ABSTRACT
OBJECTIVE: To evaluate the trends in hospitalizations for children with trisomy 18 over time and to determine the rate of invasive procedures on these children, using a large inpatient database. STUDY DESIGN: A retrospective analysis using the Kids' Inpatient Database from 1997 to 2016 was performed for trisomy 18. We evaluated survival to discharge as well as the presence of pulmonary, skeletal, neurologic, gastrointestinal, renal, and hematologic/bleeding problems. We also searched for the following interventions, if performed: gastrostomy tube placement, tracheostomy, or cardiac procedure. RESULTS: Over this period 10 151 admissions occurred in children with a diagnosis of trisomy 18. Between 1997 and 2016, the number of children admitted annually with trisomy 18 increased 74% from 1036 to 1798. The proportion of patients born prematurely remained stable at 14%-16% throughout the study. Gastrostomy tube placement increased 12-fold during the study period, tracheostomy increased 11-fold, and cardiac intervention increased 5-fold. The overall mortality rate decreased in those with trisomy 18 from 32% in 1997 to 21% in 2016. CONCLUSIONS: We highlight a decreased inpatient mortality rate during the study period. The number of children undergoing interventions such as gastrostomy tube and tracheostomy increased, as did the number of children undergoing cardiac intervention. Although the number of procedures has increased with the mortality rate decreasing, it is unclear at present whether the 2 are related.
Subject(s)
Cardiac Surgical Procedures/trends , Gastrostomy/trends , Hospitalization/trends , Practice Patterns, Physicians'/trends , Tracheostomy/trends , Trisomy 18 Syndrome/surgery , Adolescent , Child , Child, Preschool , Databases, Factual , Female , Humans , Infant , Infant, Newborn , Male , Retrospective Studies , Trisomy 18 Syndrome/complications , Trisomy 18 Syndrome/mortality , United StatesABSTRACT
BACKGROUND: Surgical management has not been encouraged in patients with trisomy 18 (T18) and congenital heart diseases due to poor survival. This study aimed to investigate (1) the appropriateness of palliative surgeries followed by intracardiac repair (ICR) (i.e., two-stage ICR) for patients with a large ventricular septal defect (VSD) and T18, and (2) its impact on their long-term outcomes. METHODS: Medical charts of patients with VSD and T18 who underwent two-stage ICR at the Japanese Red Cross Medical Center between January 2005 and December 2019 were retrospectively reviewed. Demographic data, timing, and types of palliative surgeries, information related to ICR, peri- and postoperative clinical information, postoperative survival, and cause of death were collected. The long-term prognosis of patients treated with two-stage ICR was compared with that of patients treated with primary ICR and palliative surgery without ICR. RESULTS: Overall, 18 (2 male, 16 female) patients underwent two-stage ICR. Pulmonary artery banding was the initial palliative surgery in all patients after a median duration of 19.5 (range 6-194) days of life. The median age and the mean body weight at the time of ICR were 18.2 (7.6-50.7) months and 6.0 ± 1.0 kg, respectively. The mean pulmonary artery pressure and pulmonary vascular resistance index before ICR were 19.1 ± 7.3 mmHg and 3.4 ± 2.0 U m2, respectively. Overall, 17/18 (94%) patients were discharged after ICR. Fourteen (78%) patients were alive during data collection. None of the patients died of cardiac insufficiency, and the median duration of survival was 46.3 (14.3-186.4) months since birth. Most patients required cardiac medications rather than pulmonary vasodilators at the last follow-up. During the study period, three patients underwent primary ICR, and 46 underwent palliative surgery without ICR. Of those who underwent primary ICR, two died in the hospital on the first and 48th day following ICR, and the third died 179 days after the ICR. The Log-rank test revealed a significantly longer survival for the patients treated with two-stage ICR compared with those treated with palliative surgery without ICR (P = 0.003). CONCLUSION: Two-stage ICR improves the long-term survival of patients with VSDs and T18. This safe surgical strategy can also prevent pulmonary hypertension in such patients.
Subject(s)
Cardiac Surgical Procedures/methods , Heart Septal Defects, Ventricular/surgery , Trisomy 18 Syndrome/surgery , Child, Preschool , Female , Heart Defects, Congenital/surgery , Heart Septal Defects, Ventricular/mortality , Humans , Hypertension, Pulmonary/prevention & control , Infant , Infant, Newborn , Male , Palliative Care/methods , Patient Discharge , Postoperative Period , Retrospective Studies , Survival Rate , Treatment Outcome , Trisomy 18 Syndrome/mortalityABSTRACT
Congenital heart disease is exceedingly prevalent in trisomy 13 and 18. Improved survival following congenital heart surgery has been reported, however, mortality remains significantly elevated. Utilizing inpatient data on trisomy 13 and 18 from the 2003-2016 Pediatric Health Information System database, a survival model was developed and validated using data from the California Perinatal Quality Care Collaborative and the California Office of Statewide Health Planning and Development. The study cohort included 1,761 infants with trisomy 13 and 18. Two models predicting survival to 6 months of age were developed and tested. The initial model performed excellently, with a c-statistic of 0.87 and a c-statistic of 0.76 in the validation cohort. After excluding procedures performed on the day of death, the revised model's c-statistic was 0.76. Certain variables, including cardiac surgery, gastrostomy, parenteral nutrition, and mechanical ventilation, are predictive of survival to 6 months of age. This study presents a model, which potentially can inform decision-making regarding congenital heart surgery.
Subject(s)
Cardiac Surgical Procedures/mortality , Heart Defects, Congenital/mortality , Models, Statistical , Trisomy 13 Syndrome/mortality , Trisomy 18 Syndrome/mortality , Female , Follow-Up Studies , Heart Defects, Congenital/pathology , Heart Defects, Congenital/surgery , Humans , Infant, Newborn , Length of Stay , Male , Prognosis , Retrospective Studies , Risk Factors , Survival Rate , Trisomy 13 Syndrome/pathology , Trisomy 13 Syndrome/surgery , Trisomy 18 Syndrome/pathology , Trisomy 18 Syndrome/surgeryABSTRACT
BACKGROUND: Indications for extracorporeal life support (ECLS) have evolved and expanded, yet its use in trisomy 13 (T13) and trisomy 18 (T18) patients remains controversial. We reviewed the experience of the Extracorporeal Life Support Organization with ECLS in these patients to inform practice at our institution. METHODS: The Extracorporeal Life Support Organization registry was queried for all patients younger than 18 y with an International Classification of Diseases, Ninth Edition/Tenth Edition code for T13 or T18 from 2000 to 2018. Basic demographics, ECLS details, and clinical outcomes were recorded. Descriptive statistics were performed. RESULTS: Twenty-eight patients were identified (15 with T13; 13 with T18), representing 0.06% (28 of 46,901) of pediatric ECLS cannulations. The median weight was 3.5 kg (range, 1.4-13), and age at cannulation was 52 d (range, 0 d-6.8 y). Time on ECLS ranged from 13 to 478 h (median, 114). Cardiac defects were diagnosed in 19 (68%) patients, of which 13 (46%) underwent surgical repair. Median oxygenation index pre-ECLS was 45. Venoarterial cannulations accounted for 82% of patients, whereas 14% underwent venovenous cannulation. Overall survival to hospital discharge was 46% with 86% of patients experiencing one or more complications. There were no survivors when cannulation continued past 12 d. CONCLUSIONS: Although complications are frequent, the mortality rate in patients with T13 and T18 remains within the reported range for the general pediatric population. T13 and T18 alone should not be viewed as absolute contraindications to ECLS within the pediatric population but rather considered during the evaluation of a patient's potential candidacy.
Subject(s)
Extracorporeal Membrane Oxygenation/adverse effects , Life Support Care/statistics & numerical data , Trisomy 13 Syndrome/therapy , Trisomy 18 Syndrome/therapy , Blood Gas Analysis/statistics & numerical data , Catheterization/adverse effects , Catheterization/statistics & numerical data , Child , Child, Preschool , Extracorporeal Membrane Oxygenation/statistics & numerical data , Female , Humans , Infant , Infant, Newborn , Life Support Care/methods , Male , Registries/statistics & numerical data , Retrospective Studies , Treatment Outcome , Trisomy 13 Syndrome/blood , Trisomy 13 Syndrome/mortality , Trisomy 18 Syndrome/blood , Trisomy 18 Syndrome/mortalityABSTRACT
Trisomy 18 (T18) and trisomy 13 (T13) are major concerns in prenatal genetic testing due to their poor prognosis; very low birth weight (VLBW) is also a concern in neonatology. The aim of this study was to investigate the mortality and morbidity of VLBW infants diagnosed with T18/T13 in Japan, compared with those with no birth defects (BD-). Maternal and neonatal data were collected prospectively from infants weighing <1501 g and were admitted to centers of the Neonatal Research Network of Japan during 2003 to 2016. Among 60,136 infants, 563 and 60 was diagnosed with T18 and T13, respectively. Although the age of mothers of infants with T18/T13 was higher, the frequency of maternal complications was lower than those with BD-. With maternal and neonatal characteristic adjustments, T18/T13 had a higher incidence of each morbidity when compared with BD-. Mortality rates in the NICU were 70, 77, and 5.8% for T18, T13, and BD-, respectively, while the survival discharge rates of T18 and T13 were 29.5 and 23.3%, respectively, which was significantly higher than previous reports. This was the first nationwide survey for VLBW infants with T18/T13 in Japan; this novel data will be relevant and useful for prenatal genetic counseling and perinatal management. Although T18/T13 were considered to be fatal in the past, with proper epidemiological information, discussions with affected families, and compassionate patient care, the mortality rate of T18/T13 can be improved.
Subject(s)
Infant, Newborn, Diseases/epidemiology , Infant, Very Low Birth Weight , Trisomy 13 Syndrome/epidemiology , Trisomy 18 Syndrome/epidemiology , Abnormalities, Multiple/epidemiology , Abnormalities, Multiple/genetics , Asian People/genetics , Chorioamnionitis/epidemiology , Comorbidity , Disease Susceptibility , Female , Fetal Membranes, Premature Rupture/epidemiology , Humans , Incidence , Infant, Newborn , Infant, Premature, Diseases/epidemiology , Intensive Care Units, Neonatal , Japan/epidemiology , Male , Maternal Age , Pregnancy , Pregnancy Complications/epidemiology , Prognosis , Prospective Studies , Trisomy 13 Syndrome/ethnology , Trisomy 13 Syndrome/mortality , Trisomy 18 Syndrome/ethnology , Trisomy 18 Syndrome/mortalityABSTRACT
There has been substantial controversy regarding treatment of congenital heart defects in infants with trisomies 13 and 18. Most reports have focused on surgical outcomes versus expectant treatment, and rarely there has been an effort to consolidate existing evidence into a more coherent way to help clinicians with decision-making and counseling families. An extensive review of the existing literature on cardiac surgery in patients with these trisomies was conducted from 2004 to 2020. The effects of preoperative and perioperative factors on in-hospital and long-term mortality were analyzed, as well as possible predictors for postoperative chronic care needs such as tracheostomy and gastrostomy. Patients with minimal or no preoperative pulmonary hypertension and mechanical ventilation undergoing corrective surgery at a weight greater than 2.5 kg suffer from lower postoperative mortality. Infants with lower-complexity cardiac defects are likely to benefit the most from surgery, although their expected mortality is higher than that of infants without trisomy. Omphalocele confers an increased mortality risk regardless of cardiac surgery. Gastrointestinal comorbidities increased the risk of gastrostomy tube placement, while those with prolonged mechanical ventilation and respiratory comorbidities are more likely to require tracheostomy. Cardiac surgery is feasible in children with trisomies 13 and 18 and can provide improved long-term results. However, this is a clinically complex population, and both physicians and caretakers should be aware of the long-term challenges these patients face following surgery when discussing treatment options.
Subject(s)
Cardiac Surgical Procedures/methods , Clinical Decision-Making , Heart Defects, Congenital/surgery , Trisomy 13 Syndrome/surgery , Trisomy 18 Syndrome/surgery , Child , Child, Preschool , Female , Heart Defects, Congenital/mortality , Humans , Infant , Infant, Newborn , Male , Practice Guidelines as Topic , Respiration, Artificial , Risk Factors , Tracheostomy , Treatment Outcome , Trisomy , Trisomy 13 Syndrome/mortality , Trisomy 18 Syndrome/mortalityABSTRACT
The "Baby Doe" case of the early 1980s was marked by considerable controversy, primarily regarding the legal response of the federal government to the case at the time. In the decades that followed, the decision-making for children with trisomy 21, like Baby Doe, has been substantially reevaluated. The data, the assumptions about quality of life that were based on those data, and the ethical principles underpinning the decision-making in the Baby Doe case have all evolved significantly over time. The present strategies for decision-making for children with trisomy 13 and 18 appear to be following a similar pattern. The data, quality-of-life assumptions based on those data, and even the ethical principles underlying the decision-making for these children are currently being reexamined. Children with trisomy 13 and 18 are, in this regard, the next Baby Doe(s).
Subject(s)
Clinical Decision-Making/ethics , Down Syndrome/therapy , Trisomy 13 Syndrome/therapy , Trisomy 18 Syndrome/therapy , Child Development , Esophageal Atresia , Humans , Infant, Newborn , Kaplan-Meier Estimate , Parents , Quality of Life , Trisomy 13 Syndrome/mortality , Trisomy 18 Syndrome/mortality , Withholding Treatment/ethics , Withholding Treatment/legislation & jurisprudenceABSTRACT
The purpose of this study is to analyze the experience of hope that appears in a parent's blog presenting everyday life while caring for a child with Trisomy 18 (Edwards syndrome). The author, Rebekah Peterson, began her blog on 17 March 2011 and continues to post information on her son Aaron's care. The analysis of hope in the blog is carried out using a mixed methodology: initial and focused coding using Charmaz's constructed grounded theory and elements of Colaizzi's method. Each aspect of hope is coded through the blog author's statements, from which three main aspects of hope emerge: hope for the longest possible presence of Aaron with his family, hope for control over situations, pain, and symptoms, and existential facets of hope. These various aspects reveal to what extent the experience of hope is unique. Additionally, analyzing the experience of parental hope uncovers the additional problem of inappropriate communication by health care professionals (HCPs) in intensive care units, particularly when discussing the termination of causal treatment. The problem may be solved through proper education for HCPs and serious consideration of parental involvement in order to properly elaborate guidelines on this issue. The three main aspects of parental hope discussed in this paper might expand knowledge on the issue, helping HCPs to better understand the parents' experience of care and to help sustain parental hope in pediatric palliative care.
Subject(s)
Hope , Palliative Care , Parents/psychology , Pediatrics , Professional-Family Relations , Trisomy 18 Syndrome , Blogging , Child , Communication , Female , Grounded Theory , Humans , Longitudinal Studies , Male , Qualitative Research , Trisomy 18 Syndrome/mortality , Trisomy 18 Syndrome/psychologyABSTRACT
This case series aimed to characterize the clinical features, management, and outcomes of apnea in infants with trisomy 18. Participants in this study were infants with trisomy 18 who were born alive and admitted to the neonatal intensive care unit in Kyushu University Hospital from 2000 to 2018. Retrospective analysis was performed on clinical data recorded in our department. Twenty-seven infants with trisomy 18 were admitted to our hospital during the study period, of which 25 (nine males, 16 females) were enrolled as eligible participants in this study. Among them, 14 started presenting with apnea from median 3.5 days of age (range 0-47d). In these infants with apnea, eight received respiratory support of positive pressure ventilation (PPV). The 1-year survival rate of infants in the PPV group was higher than that of non-PPV-supported infants (5 out of 8 vs 0 out of 6 infants). Five PPV-supported infants received a diagnosis of epilepsy, which was controlled by antiepileptic drugs. Postnatal respiratory intervention provides better prognosis in infants with trisomy 18. Improved survival leads to accurate diagnosis and treatment of apneic events in association with epilepsy. WHAT THIS PAPER ADDS: Respiratory support is effective against apnea in infants with trisomy 18. Intervention with ventilation provides a higher chance of prolonged survival. Improved survival leads to the accurate diagnosis and treatment of epilepsy-associated apnea.
Subject(s)
Apnea , Epilepsy , Intensive Care Units, Neonatal , Outcome Assessment, Health Care , Positive-Pressure Respiration , Trisomy 18 Syndrome , Apnea/diagnosis , Apnea/etiology , Apnea/mortality , Apnea/therapy , Epilepsy/diagnosis , Epilepsy/mortality , Epilepsy/therapy , Female , Humans , Infant , Infant, Newborn , Male , Retrospective Studies , Trisomy 18 Syndrome/complications , Trisomy 18 Syndrome/diagnosis , Trisomy 18 Syndrome/mortality , Trisomy 18 Syndrome/therapyABSTRACT
Until recently, trisomy 18 was considered a disease incompatible with life, with a high percentage of electively terminated pregnancies. The usual behavior was denial of treatment. But some medical interventions have changed the survival of children. A search for articles published in the PubMed database on the latest medical decisions in newborns with trisomy 18 was done. Two main subjects were examined: (1) the chances of survival and (2) the perception of quality of life. Trisomy 18 is no longer considered a disease incompatible with life, and the discussion has shifted towards the type of treatment that is appropriate to initiate at birth. There are two medical attitudes towards these children: either palliative care or life-prolonging interventions. With medical intervention, the survival is as high as 23% at 5 years of age. Regarding the quality of life, all decision-makers emphasize the possibility of taking the child home. The physicians' perception is more pessimistic than that of the parents. Only a few children benefit from medical interventions.Conclusion: There is a rethinking of treatment behavior in children with trisomy 18. The possible quality of life achieved should be further investigated. It seems inappropriate to simply dismiss medical interventions.What is Known⢠Until recently, trisomy 18 was considered a disease incompatible with life. The most common behavior was abortion and denial of treatment.What is New⢠It is no longer considered a lethal disease. The type of medical intervention that is appropriate to perform is now being discussed. Selected children benefit from an interventionist approach.
Subject(s)
Quality of Life , Trisomy 18 Syndrome/therapy , Attitude of Health Personnel , Child, Preschool , Decision Making/ethics , Humans , Infant , Infant, Newborn , Palliative Care/ethics , Parents/psychology , Self-Help Groups , Trisomy 18 Syndrome/mortalityABSTRACT
PURPOSE OF REVIEW: The implementation of palliative care at birth has led to a significant rise in the number of couples who choose to continue with pregnancies complicated by life-limiting malformations (LLMs). Prenatal counselling and appropriate antenatal/perinatal management in these cases are poorly studied and may pose significant challenges. The purpose of this review is to outline specific obstetric risks and to suggest management for mothers who choose to continue with pregnancies with the most common LLMs. RECENT FINDINGS: In pregnancies complicated by LLMs where parents opt for expectant management, clinicians should respect parental wishes, whilst openly sharing potential serious maternal medical risks specific for the identified abnormalities. The focus of both antenatal and perinatal care should be maternal wellbeing rather than foetal survival. Follow-up ultrasound examinations and maternal surveillance should be aimed at achieving timely diagnosis and effective management of obstetric complications. A clear perinatal plan, agreed with the couples by a multi-disciplinary team including a foetal medicine specialist, a neonatologist and a geneticist, is crucial to reduce maternal morbidity. SUMMARY: This review provides a useful framework for clinicians who face the challenges of counselling and managing cases complicated by LLMs where parents opt for pregnancy continuation.
Subject(s)
Congenital Abnormalities/mortality , Congenital Abnormalities/therapy , Palliative Care/methods , Pregnancy Complications/therapy , Prenatal Care/methods , Anencephaly/mortality , Congenital Abnormalities/diagnosis , Female , Genetic Counseling , Holoprosencephaly/mortality , Humans , Hydrops Fetalis/mortality , Neonatology/organization & administration , Obstetrics/organization & administration , Patient Care Team , Pregnancy , Pregnancy Complications/etiology , Risk , Triploidy , Trisomy 13 Syndrome/mortality , Trisomy 18 Syndrome/mortality , Turner Syndrome/mortality , UltrasonographyABSTRACT
The aim of the study is to determine the prevalence, outcomes, and survival (among live births [LB]), in pregnancies diagnosed with trisomy 13 (T13) and 18 (T18), by congenital anomaly register and region. Twenty-four population- and hospital-based birth defects surveillance registers from 18 countries, contributed data on T13 and T18 between 1974 and 2014 using a common data-reporting protocol. The mean total birth prevalence (i.e., LB, stillbirths, and elective termination of pregnancy for fetal anomalies [ETOPFA]) in the registers with ETOPFA (n = 15) for T13 was 1.68 (95% CI 1.3-2.06), and for T18 was 4.08 (95% CI 3.01-5.15), per 10,000 births. The prevalence varied among the various registers. The mean prevalence among LB in all registers for T13 was 0.55 (95%CI 0.38-0.72), and for T18 was 1.07 (95% CI 0.77-1.38), per 10,000 births. The median mortality in the first week of life was 48% for T13 and 42% for T18, across all registers, half of which occurred on the first day of life. Across 16 registers with complete 1-year follow-up, mortality in first year of life was 87% for T13 and 88% for T18. This study provides an international perspective on prevalence and mortality of T13 and T18. Overall outcomes and survival among LB were poor with about half of live born infants not surviving first week of life; nevertheless about 10% survived the first year of life. Prevalence and outcomes varied by country and termination policies. The study highlights the variation in screening, data collection, and reporting practices for these conditions.
Subject(s)
Trisomy 13 Syndrome/epidemiology , Trisomy 18 Syndrome/epidemiology , Female , Humans , Live Birth , Mortality , Population Surveillance , Pregnancy , Pregnancy Outcome , Prenatal Diagnosis , Prevalence , Registries , Trisomy 13 Syndrome/genetics , Trisomy 13 Syndrome/mortality , Trisomy 18 Syndrome/genetics , Trisomy 18 Syndrome/mortalityABSTRACT
Trisomy 18 is a genetic disease resulting from an extra chromosome 18, characterized by a broad clinical spectrum, poor prognosis and low rates of survival. This is the case of a 12 year-old girl diagnosed with full trisomy 18, and multiple malformations, including Dandy-Walker Syndrome and congenital heart defects on long term survival. At nine months, a new echocardiogram showed a double outlet right ventricle, significant pulmonary stenosis, patent ductus arteriosus and ventricular septal defect. Cardiac surgery was performed at one year and seven months. Early surgical intervention and multidisciplinary follow-up may change the clinical outcome of the disease. Further studies are required to evaluate the benefit of invasive procedures such as cardiac surgery on survival of patients with trisomy 18.
Subject(s)
Dandy-Walker Syndrome/complications , Time Factors , Trisomy 18 Syndrome/complications , Child , Dandy-Walker Syndrome/diagnostic imaging , Dandy-Walker Syndrome/mortality , Female , Humans , Tomography, X-Ray Computed/methods , Trisomy 18 Syndrome/diagnostic imaging , Trisomy 18 Syndrome/mortalityABSTRACT
Children with trisomy 18 that survive beyond the neonatal period have multiple congenital anomalies, neurodevelopmental disability, and high mortality rates. The experience of children with trisomy 18 who receive pediatric palliative care services is largely unknown. We conducted a retrospective review of children with trisomy 18 receiving pediatric palliative care services at both Boston Children's Hospital, USA and Great Ormond Street Hospital, UK from January 1, 2004 to January 1, 2015. Fifty-eight children with trisomy 18 were referred to pediatric palliative care, 38 in the United Kingdom, 20 in the United States. Median age at referral was 19 days (2-89) in the United Kingdom, and 25 days (1-463) in the United States. Median length of time being followed by pediatric palliative care was 32 days (1-1,637) in the United Kingdom and 67 days (3-2,442) in the United States. The only significant difference in the two cohorts (p = .001) was in likelihood of receiving cardiac surgical intervention-37% in the United States, 0% the United Kingdom. Children with trisomy 18 receive pediatric palliative care services, with variable age at referral and for a variable length of time. Further research is needed to understand the experience of children with trisomy 18 and their families receiving pediatric palliative care services.
Subject(s)
Palliative Care , Referral and Consultation , Trisomy 18 Syndrome/drug therapy , Disease Management , Health Care Surveys , Humans , Infant , Infant, Newborn , Prognosis , Survival Analysis , Trisomy 18 Syndrome/diagnosis , Trisomy 18 Syndrome/mortality , Trisomy 18 Syndrome/therapy , United Kingdom/epidemiology , United States/epidemiologyABSTRACT
BACKGROUND: Despite Trisomy 13 and 18 being among the most fatal congenital anomalies, limited information exists about resource utilization and factors associated with length of stay (LOS) and total hospital charges (THC) for these anomalies. METHODS: We studied data sets of the patient discharge data set from the California Office of Statewide Health Planning and Development from 2006 to 2010, to determine differences in resource utilization for survivors and non-survivors and identify the predictors of LOS and total hospital charges. Descriptive statistics were assessed for demographic and clinical characteristics. General linear regression models were used to identify predictors of LOS and THC. RESULTS: Seventy-six Trisomy 13 and 115 Trisomy 18 patients were identified, for whom inpatient mortality was 27.6% and 20.9%, respectively. In patients with Trisomy 13, after adjusting for gender, ethnicity, advanced directive (DNR), insurance and co-morbidities on multivariate analysis, the provision of more than 96 h of mechanical ventilation was associated with significantly increased LOS (standard error, SE) by 18.0 ± 5.3 days and THC (SE) by $399,000 ± $85,000. In terms of insurance type, patients with private coverage had 10.8 ± 4.9 days more than patients with Medicaid. In patients with Trisomy 18, on multivariate analysis, after adjusting for gender, ethnicity, DNR, insurance and co-morbidities, more than 96 h of mechanical ventilation was associated with increased LOS (SE) by 36.8 ± 6.8 days and THC (SE) by $365,000 ± $59,000. CONCLUSION: Understanding predictors that are associated with longer LOS and higher THC may be associated in hospital resource allocation for this vulnerable population of infants.
Subject(s)
Hospital Charges , Length of Stay/economics , Trisomy 13 Syndrome/economics , Trisomy 18 Syndrome/economics , California , Facilities and Services Utilization/economics , Female , Hospital Mortality , Humans , Infant, Newborn , Length of Stay/statistics & numerical data , Male , Respiration, Artificial/economics , Retrospective Studies , Treatment Outcome , Trisomy 13 Syndrome/mortality , Trisomy 13 Syndrome/therapy , Trisomy 18 Syndrome/mortality , Trisomy 18 Syndrome/therapyABSTRACT
Infants with trisomy 18 (T18) previously had a poor prognosis; however, the intensive care of these patients has markedly diversified the prognosis. We investigated the current situation of patients with T18, clarified factors for survival discharge, and surveyed actual home healthcare. A total of 117 patients with T18 admitted to nine institutions between 2000 and 2015 were retrospectively investigated. After excluding four patients whose outcomes were unclear, we divided 113 patients into two groups-the survival discharge group (n = 52) and the death discharge group (n = 61)-and compared maternal factors, perinatal factors, neonatal factors, and therapeutic factors between the groups. In addition, home healthcare, readmission, utilization of respite care and home nursing, and cause of death among the survival group were surveyed. Fifty-two (44%) patients with T18 survived at discharge and their 1-year survival rate was 29%. The survival group had a longer gestation period, larger physique, and longer survival time, compared to the death group. Independent factors associated with survival discharge were the absence of an extremely low birthweight infant (ELBWI), the absence of esophageal atresia and patent ductus arteriosus, and cardiovascular surgery. All surviving patients required some home healthcare. The most frequent cause of death was a respiratory disorder. We recommend discussing the treatment strategy with families in the presence of neonatologists or pediatric surgeons, who can explain differences in prognosis, based on the gestation period, birthweight, severity of cardiovascular disease, and cardiovascular surgery.
Subject(s)
Cardiovascular Diseases/diagnosis , Gestational Age , Patient Discharge/trends , Trisomy 18 Syndrome/diagnosis , Adult , Birth Weight , Cardiovascular Diseases/complications , Cardiovascular Diseases/mortality , Cardiovascular Diseases/surgery , Female , Home Care Services , Home Nursing/methods , Humans , Infant , Infant Mortality/trends , Infant, Newborn , Male , Pregnancy , Prognosis , Retrospective Studies , Survival Analysis , Trisomy 18 Syndrome/complications , Trisomy 18 Syndrome/mortality , Trisomy 18 Syndrome/surgeryABSTRACT
Congenital heart defects are common among patients with trisomy 13 and 18; surgical repair has been controversial and rarely studied. We aimed to assess the frequency of cardiac surgery among admissions with trisomy 13 and 18, and evaluate their associations with resource use, complications, and mortality compared to admissions without these diagnoses. We evaluated congenital heart surgery admissions of ages < 18 years in the 1997, 2000, 2003, 2006, and 2009 Kids' Inpatient Database. Bivariate and multivariate analyses examined the adjusted association of trisomy 13 and 18 on resource use, complications, and inpatient death following congenital heart surgery. Among the 73,107 congenital heart surgery admissions, trisomy 13 represented 0.03% (n = 22) and trisomy 18 represented 0.08% (n = 58). Trisomy 13 and 18 admissions were longer; trisomy 13: 27 days vs. 8 days, p = 0.003; trisomy 18: 16 days vs. 8 days, p = 0.001. Hospital charges were higher for trisomy 13 and 18 admissions; trisomy 13: $160,890 vs. $87,007, p = 0.010; trisomy 18: $160,616 vs. $86,999, p < 0.001. Trisomy 18 had a higher complication rate: 52% vs. 34%, p < 0.006. For all cardiac surgery admissions, mortality was 4.5%; trisomy 13: 14% and trisomy 18: 12%. In multivariate analysis, trisomy 18 was an independent predictor of death: OR 4.16, 95% CI 1.35-12.82, p = 0.013. Patients with trisomy 13 and 18 represent 0.11% of pediatric congenital heart surgery admissions. These patients have a 2- to 3.4-fold longer hospital stay and double hospital charges. Patients with trisomy 18 have more complications and four times greater adjusted odds for inpatient death.
Subject(s)
Cardiac Surgical Procedures/statistics & numerical data , Heart Defects, Congenital/epidemiology , Patient Acceptance of Health Care/statistics & numerical data , Trisomy 13 Syndrome/complications , Trisomy 18 Syndrome/complications , Adolescent , Cardiac Surgical Procedures/adverse effects , Cardiac Surgical Procedures/economics , Child , Child, Preschool , Databases, Factual , Female , Heart Defects, Congenital/etiology , Heart Defects, Congenital/surgery , Hospital Charges/statistics & numerical data , Hospital Mortality , Hospitalization/statistics & numerical data , Humans , Length of Stay/economics , Length of Stay/statistics & numerical data , Male , Postoperative Complications/epidemiology , Risk Factors , Trisomy 13 Syndrome/mortality , Trisomy 13 Syndrome/surgery , Trisomy 18 Syndrome/mortality , Trisomy 18 Syndrome/surgerySubject(s)
Aneuploidy , Klinefelter Syndrome/mortality , Sex Chromosome Disorders of Sex Development/mortality , Sex Chromosome Disorders/mortality , Trisomy 18 Syndrome/mortality , XYY Karyotype/mortality , Chromosomes, Human, X/chemistry , Chromosomes, Human, X/genetics , Chromosomes, Human, Y/chemistry , Ductus Arteriosus, Patent/genetics , Ductus Arteriosus, Patent/mortality , Ductus Arteriosus, Patent/pathology , Female , Heart Defects, Congenital/genetics , Heart Defects, Congenital/mortality , Heart Defects, Congenital/pathology , Heart Septal Defects, Atrial/genetics , Heart Septal Defects, Atrial/mortality , Heart Septal Defects, Atrial/pathology , Heart Septal Defects, Ventricular/genetics , Heart Septal Defects, Ventricular/mortality , Heart Septal Defects, Ventricular/pathology , Humans , Infant , Infant, Newborn , Karyotype , Klinefelter Syndrome/genetics , Klinefelter Syndrome/pathology , Male , Sex Chromosome Aberrations , Sex Chromosome Disorders/genetics , Sex Chromosome Disorders/pathology , Sex Chromosome Disorders of Sex Development/genetics , Sex Chromosome Disorders of Sex Development/pathology , Survival Analysis , Trisomy/genetics , Trisomy/pathology , Trisomy 18 Syndrome/genetics , Trisomy 18 Syndrome/pathology , XYY Karyotype/genetics , XYY Karyotype/pathologyABSTRACT
We sought to evaluate the mortality, risk factors for mortality, and resource utilization following cardiac interventions in trisomy 13 (T13) and 18 (T18) children. All T13 and T18 children who underwent a cardiac intervention from January 1999 to March 2015 were identified from the Pediatric Health Information System database. Data collected included demographics, type of congenital heart disease (CHD), cardiac interventions, comorbidities, length of stay (LOS), hospital charges, and deaths (within 30 days). Logistic regression analysis was used to determine factors associated with mortality. There were 49 (47% females) T13 and 140 (67% females) T18 subjects. The two cohorts were similar in distribution for race, geographic region, insurance type, and median household income. The most common CHD in both groups was a shunt lesion followed by conotruncal defects. Compared to T18, the T13 cohort had higher mortality (29% vs. 12%), tracheostomies (12% vs. 4%), gastrostomies (18% vs. 6%), and overall resource use (P < 0.05 for all). White race (OR 0.23, 95% CI 0.06-0.81) in T13 and older age (in weeks) at surgery in T18 (OR 0.75, 95% CI 0.64-0.86) were associated with lower mortality. A select group of T13 and T18 CHD patients can undergo successful cardiac interventions, albeit with a higher mortality and resource use. T13 patients have higher mortality and resource use compared to T18. In T13 and T18 patients, interventions for CHD may be an acceptable and ethical option following a careful individualized selection and counseling by a team of experts.
Subject(s)
Cardiac Surgical Procedures/statistics & numerical data , Heart Defects, Congenital/surgery , Patient Acceptance of Health Care/statistics & numerical data , Trisomy 13 Syndrome/complications , Trisomy 18 Syndrome/complications , Cardiac Surgical Procedures/adverse effects , Child , Cohort Studies , Databases, Factual , Female , Heart Defects, Congenital/complications , Heart Defects, Congenital/mortality , Humans , Infant , Length of Stay/statistics & numerical data , Longitudinal Studies , Male , Retrospective Studies , Risk Factors , Survival Rate , Trisomy 13 Syndrome/mortality , Trisomy 13 Syndrome/surgery , Trisomy 18 Syndrome/mortality , Trisomy 18 Syndrome/surgeryABSTRACT
OBJECTIVE: We assessed survival, hospital length of stay (LOS), and costs of medical care for infants with lethal congenital malformations, and also examined the relationship between medical and surgical therapies and survival. STUDY DESIGN: Retrospective cohort study including infants born 1998-2009 with lethal congenital malformations, identified using a longitudinally linked maternal/infant database. RESULTS: The cohort included 786 infants: trisomy 18 (T18, n = 350), trisomy 13 (T13, n = 206), anencephaly (n = 125), bilateral renal agenesis (n = 53), thanatophoric dysplasia/achondrogenesis/lethal osteogenesis imperfecta (n = 38), and infants > 1 of the birth defects (n = 14). Compared to infants without birth defects, infants with T18, T13, bilateral renal agenesis, and skeletal dysplasias had longer survival rates, higher inpatient medical costs, and longer LOS. CONCLUSION: Care practices and survival have changed over time for infants with T18, T13, bilateral renal agenesis, and skeletal dysplasias. This information will be useful for clinicians in counseling families and in shaping goals of care prenatally and postnatally.